NM
ADPT icon

Newtyn Management’s Adaptive Biotechnologies ADPT Stock Holding History

Newtyn Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-623,690
Closed -$2M – 41
2024
Q1 		$2M Buy
623,690
+301,690
+94% +$1.17M 0.4% 30
2023
Q4 		$1.58M Buy
+322,000
New +$1.47M 0.31% 34

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Newtyn Management's ADPT Position: Q2 2024 in Review

Newtyn Management sold out of Adaptive Biotechnologies (ADPT) in Q2 2024, closing a stake of 623,690 shares — an estimated $2M sold.

Newtyn Management first reported a position in ADPT in Q4 2023 and held it in 2 quarters. The position peaked at $2M in Q1 2024. 177 funds tracked by Wall St. Rank hold ADPT as of Q2 2024.

  • Newtyn Management reported no remaining Adaptive Biotechnologies position as of Q2 2024 after selling out during the quarter.
  • Newtyn Management sold 623,690 Adaptive Biotechnologies shares in Q2 2024, an estimated $2M.
  • Newtyn Management first reported a position in Adaptive Biotechnologies in Q4 2023 and held it in 2 quarters.
  • Newtyn Management's Adaptive Biotechnologies position peaked at $2M in Q1 2024.
  • 177 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2024.

Based on Newtyn Management's 13F filing for Q2 2024, filed 14 Aug 2024.